BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim HC, Suk KT, Kim DJ, Yoon JH, Kim YS, Baik GH, Kim JB, Kim CH, Sung H, Choi JY, Han KH, Park SH. Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. World J Gastroenterol 2014; 20(3): 745-754 [PMID: 24574748 DOI: 10.3748/wjg.v20.i3.745] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Chen R, Gan Y, Ge N, Chen Y, Ma H, Wang Y, Zhang B, Wang Y, Ye S, Luo J, Ren Z. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching: TACE versus RFA for early HCC. Journal of Gastroenterology and Hepatology 2016;31:442-9. [DOI: 10.1111/jgh.13077] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
2 Liu Y, Xue D, Tan S, Zhang Q, Yang X, Li Y, Zhu B, Niu S, Jiang L, Wang X. Comparison of macrovascular invasion-free survival in early-intermediate hepatocellular carcinoma after different interventions: A propensity score-based analysis. J Cancer 2019;10:4063-71. [PMID: 31417651 DOI: 10.7150/jca.29850] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Bermo M, Matesan MC, Itani M, Behnia F, Vesselle HJ. Hepatopulmonary shunting on Tc99m-MAA liver mapping: correlation with dynamic cross-sectional imaging and description of different shunting patterns. Abdom Radiol 2018;43:3001-8. [DOI: 10.1007/s00261-018-1602-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Schobert IT, Savic LJ, Chapiro J, Bousabarah K, Chen E, Laage-Gaupp F, Tefera J, Nezami N, Lin M, Pollak J, Schlachter T. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE. Eur Radiol 2020;30:5663-73. [PMID: 32424595 DOI: 10.1007/s00330-020-06931-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
5 Tong H, Wei B, Chen S, Xie YM, Zhang MG, Zhang LH, Huang ZY, Tang CW. Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study. Oncotarget 2017;8:48303-12. [PMID: 28430638 DOI: 10.18632/oncotarget.15684] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
6 Chen R, Gan Y, Ge N, Chen Y, Wang Y, Zhang B, Wang Y, Ye S, Ren Z. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study. J Vasc Interv Radiol 2016;27:1829-36. [PMID: 27553917 DOI: 10.1016/j.jvir.2016.06.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
7 Mähringer-Kunz A, Weinmann A, Schmidtmann I, Koch S, Schotten S, Pinto Dos Santos D, Pitton MB, Dueber C, Galle PR, Kloeckner R. Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma. BMC Cancer 2018;18:489. [PMID: 29703174 DOI: 10.1186/s12885-018-4407-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
8 Kohi MP. Gender-Related Differences in Hepatocellular Carcinoma: Does Sex Matter? J Vasc Interv Radiol 2016;27:1338-41. [PMID: 27566425 DOI: 10.1016/j.jvir.2016.06.035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
9 Zhou ZG, Zheng XR, Zhou Q, Shi M, Zhang YJ, Guo RP, Yuan YF, Chen MS, Lin XJ, Lao XM, Li SP. Impact of oral anti-hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization. Chin J Cancer 2015;34:205-16. [PMID: 26058595 DOI: 10.1186/s40880-015-0017-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
10 Roberts SK, Gazzola A, Lubel J, Gow P, Bell S, Nicoll A, Dev A, Fink MA, Sood S, Knight V, Hong T, Paul E, Mishra G, Majeed A, Kemp W; Melbourne Liver Group. Treatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival. Scand J Gastroenterol 2018;53:1368-75. [PMID: 30394145 DOI: 10.1080/00365521.2018.1517277] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
11 Guo Z, Zhong Y, Hu B, Jiang JH, Li LQ, Xiang BD. Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma within Milan criteria: A propensity score matching analysis. Medicine (Baltimore) 2017;96:e8933. [PMID: 29390426 DOI: 10.1097/MD.0000000000008933] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
12 Kang YJ, Lee BC, Kim JK, Yim NY, Kim HO, Cho SB, Jeong YY. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2020;43:55-64. [PMID: 31646378 DOI: 10.1007/s00270-019-02349-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
13 Falkson SR, Bhambhvani HP, Hayden Gephart M. Hepatocellular Carcinoma Brain Metastases: A Single-Institution Experience. World Neurosurgery 2020;140:e27-32. [DOI: 10.1016/j.wneu.2020.03.189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]